This article is more than 5 years old. Information may no longer be current.
Patients with ankylosing spondylitis had better sleep quality following anti-TNF vs NSAID treatment
Click Here to Manage Email Alerts
Patients with ankylosing spondylitis had lower disease activity and better sleep quality after treatment with anti-tumor necrosis factor therapy compared with NSAIDs, according to results.
Researchers recorded the demographic and treatment characteristics, spinal mobility measurements, disease activity measurements and sleep questionnaire results of 59 patients (78% men) with ankylosing spondylitis. Researchers performed a polysomnography exam on each patient for the evaluation of sleep patterns.
Overall, 47.5% of patients received anti-tumor necrosis factor (TNF) therapy and 52.5% received NSAIDs. Compared with the anti-TNF group, researchers found a significantly higher prevalence of daytime fatigue, waking up with a headache and insufficient-fragmented sleep in the NSAID group. According to results, patients in the NSAID group had a higher Pittsburgh Sleep Quality Index, but no significant difference was found in terms of total Epworth Sleepiness Scale scores between the two groups.
Researchers noted significantly greater total sleep time and sleep efficiency among patients treated with anti-TNF therapy, as well as a significantly lower sleep onset latency, number of awakenings and arousal index. Stage 1 sleep was significantly shorter in patients on anti-TNF therapy and the rapid eye movement sleep period was significantly longer, according to results. – by Casey Tingle
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts